News Stocks Indegene Limited Appoints Ms. Jill Mary De Simone as Independent Director for Three-Year TermIndegene Limited Appoints Ms. Jill Mary De Simone as Independent Director for Three-Year Term
Indegene Limited has appointed Ms. Jill Mary De Simone as Additional Director (Non-Executive Independent Director) for a three-year term from January 22, 2026 to January 21, 2029, subject to shareholder approval. Ms. De Simone brings extensive biopharmaceutical industry experience, having served as former President of U.S. Oncology at Merck and held leadership roles at Teva and Bristol Myers Squibb. She currently advises preclinical companies and serves on life sciences company boards, with particular expertise in AI healthcare applications.
*this image is generated using AI for illustrative purposes only.
Indegene Limited has announced the appointment of Ms. Jill Mary De Simone as Additional Director (Non-Executive Independent Director), marking a significant addition to the company's board leadership. The appointment was approved by the Board of Directors on January 22, 2026, based on the recommendation of the Nomination and Remuneration Committee.
Appointment Details
The key parameters of Ms. De Simone's appointment are outlined below:
| Parameter: | Details |
|---|---|
| Director Name: | Ms. Jill Mary De Simone |
| DIN Number: | 11483134 |
| Position: | Additional Director (Non-Executive Independent Director) |
| Term Duration: | 3 years |
| Effective Period: | January 22, 2026 to January 21, 2029 (both days inclusive) |
| Approval Status: | Subject to shareholder approval |
Professional Background
Ms. De Simone brings extensive biopharmaceutical industry expertise to Indegene's board. She is an accomplished executive and board director with a distinguished career spanning leadership roles at major healthcare organizations. Her professional experience includes serving as former President of U.S. Oncology at Merck, where she managed full P&L responsibilities and launched transformative therapies across multiple therapeutic areas.
Her career encompasses leadership positions at prominent pharmaceutical companies including Merck, Teva, and Bristol Myers Squibb. During her tenure at these organizations, she successfully launched innovative therapies in oncology, HIV, women's health, and general medicine. Her expertise spans driving growth, innovation, and governance across global healthcare organizations.
Current Activities and Expertise
Currently, Ms. De Simone operates as an advisor to preclinical and early-stage companies, focusing on commercialization strategies and leadership transitions. She actively serves on boards of both public and private life sciences companies, bringing her strategic acumen to various organizations. Additionally, she chairs advisory boards that focus specifically on artificial intelligence applications in healthcare.
Her professional reputation centers on strategic leadership, authentic management style, and commitment to building purpose-driven organizational cultures. She demonstrates a particular passion for mentoring emerging leaders and shaping corporate governance practices within the healthcare sector.
Regulatory Compliance
Indegene has confirmed that Ms. De Simone meets all regulatory requirements for the director position. The company has affirmed that she is not debarred from holding the office of Director by virtue of any SEBI order or any other regulatory authority. This confirmation aligns with NSE circular NSE/CML/2018/24 and BSE circular LIST/COMP/14/2018-19, both dated June 20, 2018.
The appointment disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with regulatory requirements. The company has also confirmed that Ms. De Simone is not related to any existing Director of the Company, maintaining board independence standards.
Historical Stock Returns for Indegene
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.31% | -2.38% | -9.82% | -14.30% | -22.51% | -17.79% |
16
